Form 4: Crinetics CEO Exercises Stock Options, Boosts Stake

Crinetics Pharmaceuticals' President and CEO, Richard Scott Struthers, exercised stock options for 44,742 shares of common stock.

Summary

• Richard Scott Struthers, President & CEO and Director of Crinetics Pharmaceuticals, Inc. (CRNX), reported transactions on December 18, 2025.
• Struthers exercised stock options to acquire 16,342 shares of Common Stock at an exercise price of $9.28 per share.
• Additionally, Struthers exercised stock options to acquire 28,400 shares of Common Stock at an exercise price of $15.29 per share.
• Following these transactions, Struthers directly beneficially owns 364,759 shares of Common Stock.
• Indirect beneficial ownership includes 661,205 shares via Family Trust 1, 106,000 shares via Family Trust 2, 110,000 shares via Family Trust 3, 100,000 shares via Family Trust 4, and 1,000 shares via Spouse, totaling 978,205 indirect shares.
• After the exercises, Struthers retains 259,058 unexercised stock options with an exercise price of $15.29.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction where the CEO exercised stock options. This is generally a neutral event, but the increase in direct ownership can be interpreted as a slightly positive signal of management's continued confidence in the company.

Positives

• The CEO's exercise of stock options increases his direct ownership in the company, potentially signaling confidence in future performance.
• The transactions are part of a pre-arranged plan (Rule 10b5-1(c)), indicating a systematic approach to managing equity compensation.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

Insider transactions, such as the exercise of stock options, are a common occurrence in publicly traded companies, particularly for executives whose compensation packages often include equity incentives. These transactions can provide insights into management's view of the company's value, though they are often part of pre-scheduled plans.

Stakeholder Impact

• Shareholders: The increase in the CEO's direct ownership aligns his interests more closely with those of other shareholders, potentially fostering greater confidence in leadership.

Key Dates

Recommendation

The filing reports a routine insider transaction where the CEO exercised stock options. While this increases the CEO's direct ownership, signaling confidence, it is a standard compensation event and does not provide new fundamental information to change an investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while monitoring future developments.

Keywords

Crinetics Pharmaceuticals, CRNX, Stock Option Exercise, Insider Transaction, Form 4, Richard Scott Struthers, CEO, Director, Equity Compensation